oncgnostics presents novel cervical cancer triage test GynTect® at MEDICA 2015

Jena, October 29th, 2015 – At the medical trade fair MEDICA 2015 the biotech company oncgnostics GmbH (www.oncgnostics.com) presents its new product GynTect - a test for the early and reliable detection of cervical cancer – to international experts. Between 16th and 19th of November 2015 the epigenetic diagnostics specialists explain the advantages of this innovative test, compared to existing methods in cervical cancer diagnostics, such as an improved cancer risk estimation and prevention of unnecessary surgeries, at the world’s largest medical trade fair (www.medica.com).

With GynTect oncgnostics has developed a molecular test, which can clarify early and reliable if a patient with abnormal Pap smear result and/or an infection with a cancer-causing human Papillomavirus (HPV) in fact develops or has a cervical carcinoma requiring treatment.

The diagnostic test detects epigenetic changes in the cancer cells present in a cervical smear of a patient. These epigenetic changes occur in malignant cells and provide therefore an indication for the presence of a precancerous lesion or cancer. GynTect provides reliable and objective results, which facilitates largely the risk estimation during cervical cancer screening. Thus, unnecessary surgeries may be avoided. On the other hand, real precancerous lesions and carcinomas may be detected much earlier, which improves the chance for an early, successful therapy.
GynTect obtained CE IVD mark early in October 2015 and and thus has market permission to be used in diagnostic laboratories within the whole EU. Within the next months oncgnostics will release the internationally patented test not only in Germany, but also in further European countries. The company furthermore plans a release in Asia and North America.

With its team of specialists oncgnostics exhibits at booth G22 in hall 15 (Thuringian joint booth). For the first time GynTect will be presented to international expert audience. From the management of the company, Dr. Martina Schmitz, CSO, and Dr. Alfred Hansel, CEO, will be present at the booth. Dates for press interviews may be booked in advance under pr@oncgnostics.com.

MEDICA is an internationally leading tradefair for medical products, technology, laboratory equipment, diagnostics and medicals. About 4800 exhibitors from 70 countries will attend MEDICA, the leading trade fair for new products and services in the medical field.

GynTect is a registered trademark of oncgnostics GmbH.

Further information concerning cervical cancer screening:
Currently, cervical cancer screening is mainly performed by examining a smear from the portion and cervix uteri by microscopy (Pap smear). This Pap smear shows if cellular changes are present in the material. Testing for HPV shows if a patient is infected with high-risk human papillomavirus (HPV). But only a small number of HPV infections may lead to cervical cancer. In Germany, ca 90,000 so-called conizations, during which cervical tissue is removed by surgery are performed annually, based on Pap smear and further examination results – with almost half of these surgeries being unnecessary. Exact triage tests are required in order to determine if a precancerous lesion or even cancer demanding treatment is present in case of an abnormal Pap smear. GynTect® may simplify these processes for gynaecologists and patients drastically. With unequivocal results GynTect® leads to a fast and reliable identification of women with a disease requiring therapy.

Links
Visit oncgnostics at MEDICA
www.medica.de/cipp/show,lang,2/oid,28457/xa_nr,2449493/~/Web-ExhDatasheet/exh_datasheet

Please find further information concerning GynTect® and the test procedure
http://oncgnostics.com/gyntect-gebaermutterhalskrebs/info-fuer-aerzte/gyntect-testablauf

Find cost-free picture material concerning this press release, the test and the company here:
http://oncgnostics.com/downloads

About oncgnostics GmbH
Oncgnostics GmbH is spin-off from the research unit of the gynaecology department of the university women’s hospital Jena and was founded early in 2012. As a molecular diagnostic company oncgnostics is specialized on cancer diagnostics. Oncgnostics tests target epigenetic changes, so-called DNA methylations, that typically occur in cancer cells. The patented biomarkers which are evaluated using a specific algorithm are the core of the products and provide thus the basis for the company’s activities. Prominent investors have already invested into the market potential of the biotech startup, thus enabling the spin-off of the company and the development of the first product (High-Tech-Gründerfonds, Stiftung für Technologie, Innovation und Forschung Thüringen, bm-t Beteiligungsmanagement Thüringen GmbH and further investors).

Contact:
oncgnostics GmbH
Dr. Alfred Hansel
Geschäftsführer
Winzerlaer Str. 2
07745 Jena, Germany
Tel. +49 3641 508456
pr@oncgnostics.com
www.oncgnostics.com

Media Agency
Tower PR
Leutragraben 1
07743 Jena
Tel. +49 3641 87611-80
oncgnostics@tower-pr.com
www.tower-pr.com

This release was published on openPR.